Stay updated with breaking news from Michaelj labarre. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Trexquant Investment LP Buys 13,258 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the ten analysts that are presently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price […]
Steamboat Capital Partners LLC Has $7.52 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Halozyme Therapeutics (NASDAQ:HALO – Free Report) had its price target upped by HC Wainwright from $48.00 to $50.00 in a research note released on Wednesday, Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock. A number of other equities analysts also recently weighed in on HALO. TheStreet downgraded shares of […]
Gallacher Capital Management LLC Buys New Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report)‘s stock had its “market outperform” rating restated by equities research analysts at JMP Securities in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $72.00 target price on the biopharmaceutical company’s stock. JMP Securities’ target price would indicate a potential upside […]
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report)‘s stock had its “market outperform” rating restated by equities research analysts at JMP Securities in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $72.00 target price on the biopharmaceutical company’s stock. JMP Securities’ target price would indicate a potential upside […]
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report)‘s stock had its “market outperform” rating reaffirmed by JMP Securities in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $72.00 target price on the biopharmaceutical company’s stock. JMP Securities’ price target indicates a potential upside of 87.70% from the stock’s […]
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $3.55 to $3.90 for the period, compared to the consensus estimate of $3.34. The company issued revenue guidance of $915 million to $985 million, compared to the consensus […]
Charles Schwab Investment Management Inc. raised its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 0.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,698,359 shares of the biopharmaceutical company’s stock after purchasing an additional 15,902 shares during the […]